

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
25 May 2023 (25.05.2023)



(10) International Publication Number  
**WO 2023/091553 A1**

(51) International Patent Classification:

*A61K 31/40* (2006.01) *A61K 31/5685* (2006.01)  
*A61K 31/4155* (2006.01) *A61K 45/06* (2006.01)  
*A61K 31/4196* (2006.01) *A61P 35/00* (2006.01)  
*A61K 31/506* (2006.01) *G01N 33/574* (2006.01)  
*A61K 31/519* (2006.01)

(21) International Application Number:

PCT/US2022/050218

(22) International Filing Date:

17 November 2022 (17.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/280,769 18 November 2021 (18.11.2021) US

(71) Applicant: **SERMONIX PHARMACEUTICALS, INC.**  
[US/US]: 250 East Broad Street, Suite 250, Columbus, OH  
43215 (US).

(72) Inventors: **KOMM, Barry, Samuel**; Sermonix Pharma-  
ceuticals, Inc., 250 East Broad Street, Suite 250, Columbus,

OH 43215 (US). **GREENE, Geoffrey, L.**; Sermonix Phar-  
maceuticals, Inc., 250 East Broad Street, Suite 250, Colum-  
bus, OH 43215 (US).

(74) Agent: **BECKER, Daniel, M.** et al.; Fenwick & West LLP,  
801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER




FIG.2

(57) Abstract: The disclosure provides an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof, for use in methods for treating estrogen receptor positive (ER<sup>+</sup>) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER<sup>+</sup> cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (*ESR1*) gene.

[Continued on next page]

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*